Healthy Japanese
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Japanese 2. Men or women 3. Adults 4. Healthy individuals 5. Individuals whose Cmax of blood glucose level after consumption of the carbohydrate load is 140-199 mg/dL at Scr
Exclusion criteria
Exclusion criteria: 1. Individuals who are undergoing medical treatment or have a medical history of malignant tumor, heart failure, and myocardial infarction 2. Individuals who have a pacemaker or an implantable cardioverter defibrillator (ICD) 3. Individuals who are currently undergoing treatment for any of the following chronic diseases: cardiac arrhythmia, liver disorder, chronic kidney disease, cerebrovascular disorder, rheumatic disease, diabetes mellitus, dyslipidemia, hypertension, or any other chronic diseases 4. Individuals who cannot regularly take three meals (breakfast, lunch, and dinner) a day 5. Individuals who take dairy products such as milk and cheese at least four times a week 6. Individuals who are taking "Foods for Specified Health Uses" or "Foods with Functional Claims" 7. Individuals who are taking or using medications (including herbal medicines) and supplements 8. Individuals who are allergic to medications and/or the test food related products (particularly gelatin) 9. Individuals who are pregnant, lactating, or planning to become pregnant during this study 10. Individuals who have been enrolled in other clinical studies within the last 28 days before the agreement to participate in this study or plan to participate another study during this study 11. Individuals who are judged as ineligible to participate in this study by the physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. The measured value of the incremental area under the curve (IAUC) of the blood glucose level at 12 weeks after consumption (12w) [Active food 2 vs. Placebo food] | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. The measured values of the IAUC of blood glucose level at 12w [Active food 1 vs. Placebo food, Active food 3 vs. Placebo food] 2. The changes from screening (before consumption; Scr) of the IAUC of blood glucose level at 12w [Active food 2 vs. Placebo food, Active food 1 vs. Placebo food, Active food 3 vs. Placebo food] 3. The measured values and changes from Scr of the maximum blood concentration (Cmax) of blood glucose level at 12w [Active food 2 vs. Placebo food, Active food 1 vs. Placebo food, Active food 3 vs. Placebo food] 4. The measured values and changes from Scr of the fasting blood glucose level (before consumption of the carbohydrate load) and blood glucose level 30, 60, 90, and 120 minutes after consumption of the carbohydrate load at 12w [Active food 2 vs. Placebo food, Active food 1 vs. Placebo food, Active food 3 vs. Placebo food] 5. The measured values and changes from Scr of insulin, body fat percentage, fat mass, and muscle mass at 12w [Active food 2 vs. Placebo food, Active food 1 vs. Placebo food, Active food 3 vs. Placebo food] | — |
Countries
Japan
Contacts
ORTHOMEDICO Inc. R&D Department